Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms. Incyte also markets Monjuvi in the United States and Minjuvi in other markets with its partner MorphoSys for certain patients with diffuse large B-cell lymphoma.

Founded in 1991, Incyte is headquartered in Wilmington, Delaware, and serves markets in the United States and internationally through its commercial operations and partnerships. The company also maintains a research and development pipeline spanning hematology, oncology, dermatology and other immune-mediated diseases. Incyte is led by Chief Executive Officer Hervé Hoppenot, who has served in that role since 2014.

Key Stats

• Today's Range: $115.12 to $116.87
• 50-Day Range: $108.62 to $129.72
• 52-Week Range: $84.02 to $132.60
• Volume: 1.48 million shs
• Average Volume: 1.76 million shs
• Market Capitalization: $23.45 billion
• P/E Ratio: 14.57
• Dividend Yield: N/A
• Price Target: $129.90
• Consensus Rating: Hold

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 76% of companies evaluated by MarketBeat, and ranked 104th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Incyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 12 buy ratings, 12 hold ratings, and 1 sell rating.

Upside Potential

Incyte has a consensus price target of $129.90, representing about 12.3% upside from its current price of $115.71.

Amount of Analyst Coverage

Incyte has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 283.25%

Earnings Growth

Earnings for Incyte are expected to grow by 283.25% in the coming year, from $1.97 to $7.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 14.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 14.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 193.06.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 4.79. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.88% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 6.06.

Change versus previous month

Short interest in Incyte has recently increased by 0.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.49

News Sentiment

Incyte has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Incyte this week, compared to 8 articles on an average week.

Search Interest

21 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.

MarketBeat Follows

8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,659,208.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 10/25/2026
• Study update: 10/26/2026
• 2026 European Society for Medical Oncology (ESMO) Annual Congress: 10/26/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,844
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Incyte: $129.90
• High Price Target: $157.00
• Low Price Target: $90.00
• Potential Upside/Downside: +12.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.85
• Trailing P/E Ratio: 14.57
• Forward P/E Ratio: 58.74
• P/E Growth: 4.79
• Net Income: $1.29 billion
• Net Margins: 27.71%
• Pretax Margin: 33.81%
• Return on Equity: 29.93%
• Return on Assets: 22.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $5.14 billion
• Price / Sales: 4.56
• Cash Flow: $6.18 per share
• Price / Cash Flow: 18.72
• Book Value: $26.32 per share
• Price / Book: 4.40

Miscellaneous

• Outstanding Shares: 202,700,000
• Free Float: 169,861,000
• Market Cap: $23.45 billion
• Optionable: Optionable
• Beta: 0.74